Introduction
============

Asthma remains a significant burden in both developing and developed countries and causes morbidity and mortality.[@b1-dddt-12-3825] Acute exacerbation in both partially and poorly controlled asthma is the major factor contributing to morbidity and the cost of insurance, particularly in children.[@b2-dddt-12-3825] Childhood asthma is often preceded by acute, severe, and recurrent episodes of severe lower respiratory tract infections in the initial years of life.[@b3-dddt-12-3825] Nearly one-third of preschool children present with recurrent wheezing during the first 5--6 years of life.[@b4-dddt-12-3825] Among children diagnosed with recurrent wheezing or asthma, \~20% of them visit emergency departments (EDs), and 7% of them are hospitalized each year, which are major stresses for both families and health care resources.[@b5-dddt-12-3825]--[@b7-dddt-12-3825] Infants hospitalized with bronchiolitis are at significantly increased risk for both recurrent wheezing and childhood asthma.[@b8-dddt-12-3825] There are overlapping characteristics and similarities among childhood asthma, recurrent wheezing and bronchiolitis, and they may be considered to be one disease in different periods of time in some children. Therefore, the differentiation of specific reactive airway disease (RAD) entities in clinical practice is often not possible.

There has been little progress in the treatment of asthma exacerbations and long-term care over the past 20 years, as well as limited evidence for the management and prevention of preschool wheezing. High doses of inhaled steroids administered early have been proved to prevent severe asthma exacerbations in adolescents and adults while posing a risk of diminished linear growth in children with asthma.[@b9-dddt-12-3825],[@b10-dddt-12-3825] Furthermore, only hydration, oxygen, and the use of inhaled short-acting β2 agonists (SABAs) have shown evidence of being successful for the treatment of preschool childhood wheezing.[@b11-dddt-12-3825],[@b12-dddt-12-3825] Finally, there has been no effective treatment to change the long-term disease course in childhood asthma, recurrent wheezing, and bronchiolitis. Thus, identification of a better treatment to alleviate the severity of both asthma exacerbation and recurrent wheezing is of clinical importance.

There is emerging evidence that both viral and bacterial agents play important roles in the pathogenesis of both asthma exacerbations in children and recurrent wheezing in young infants.[@b13-dddt-12-3825]--[@b15-dddt-12-3825] Viral agents such as rhinovirus are significant factors in disease progression from bronchiolitis to asthma and in triggering asthma exacerbations.[@b16-dddt-12-3825] Atypical infections are common in pediatric severe asthma and severe chronic bronchitis and likely are pathogenic across the broad spectrum of RAD syndromes.[@b17-dddt-12-3825]--[@b20-dddt-12-3825] Of the causative pathogens, both *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* are strongly associated with new-onset asthma, recurrent wheezing, refractory bronchitis, acute bronchiolitis, and asthma exacerbations in children.[@b18-dddt-12-3825],[@b21-dddt-12-3825]--[@b24-dddt-12-3825] It has been reported that *C. pneumoniae* infection is common in school-age children and the immune response to chronic *C. pneumoniae* infection may intercommunicate with allergic inflammation to exacerbate asthma symptoms.[@b15-dddt-12-3825] In patients with asthma with *M. pneumoniae* infection, the use of macrolides may alleviate the symptoms of asthma. In addition, treatment with clarithromycin in patients with asthma who are colonized with mycoplasma and chlamydia species led to a reduction in pro-inflammatory and T-helper 2 cytokines, such as tumor necrosis factor-alpha, IL-5, and IL-12 mRNA, in bronchoalveolar lavage (BAL) and airway tissue.[@b25-dddt-12-3825],[@b26-dddt-12-3825] Recently, a toxin produced by *M. pneumoniae*, the community acquired respiratory distress syndrome (CARDS) toxin was identified.[@b27-dddt-12-3825] Although without statistical significance, Wood et al declared a strong correlation between poor asthma control and testing positive for CARDS toxin and concluded that CARDS toxin could deteriorate asthma symptoms.[@b28-dddt-12-3825] In addition, the upper airway colonization with capsular polysaccharide bacteria can predict subsequent recurrent wheezing and asthma diagnosis at the age of 5 years.[@b29-dddt-12-3825] These studies provide a foundation for the use of macrolides in children with asthma and recurrent wheezing.

In addition to the well-established antimicrobial activity of macrolides, they have also been characterized to have an anti-inflammatory effect.[@b30-dddt-12-3825],[@b31-dddt-12-3825] The immunomodulatory activity of macrolides has been hypothesized to have a role in the therapy of chronic inflammatory airway diseases, such as asthma and COPD.[@b32-dddt-12-3825],[@b33-dddt-12-3825] Previous serial studies[@b34-dddt-12-3825],[@b35-dddt-12-3825] in adult asthma patients have shown the benefits of 6--12 weeks of azithromycin treatment in the improvement of overall asthma symptoms. They discussed both the anti-inflammatory and antimicrobial mechanism of azithromycin, and finally proved that the anti-inflammatory effects wane after the treatment is completed, whereas the antimicrobial effects persist at 1 year of follow-up.[@b35-dddt-12-3825] Johnston et al reported that the early use of telithromycin in an acute asthma episode significantly improved symptom scores and lung function compared with a control group irrespective of the bacteriological status, implicating a non-antimicrobial mechanism.[@b36-dddt-12-3825] A recent report also showed that azithromycin treatment during respiratory syncytial virus (RSV) bronchiolitis not only reduced airway IL-8 levels and overall respiratory morbidity but also prolonged the time to a third wheezing episode.[@b37-dddt-12-3825]

A previous meta-analysis published by the Cochrane library tried to elucidate the role of macrolides for chronic asthma and reported positive effects for both forced expiratory volume in one second (FEV~1~) and asthma symptoms;[@b38-dddt-12-3825] however, each results included almost adult studies with only one child study in each result and may be insufficient to represent the true condition in children. Another meta-analysis only included children under 2 years of age, and the limited number of studies provided insufficient data for final analysis due to the heterogeneous outcomes between the included studies.[@b39-dddt-12-3825] In addition, the analysis[@b39-dddt-12-3825] included antibiotics other than macrolides and also showed no benefits. Such results may be related to the variability of adult asthma and childhood asthma. Therefore, it may be the reason why there is currently no clear evidence that the use of macrolides in the treatment of childhood wheezing is of significant clinical benefit.

Since the two meta-analyses conducted in 2014, several new reports have been published within the past 4 years.[@b37-dddt-12-3825],[@b40-dddt-12-3825]--[@b43-dddt-12-3825] To update the published data and focus this issue precisely on the specific age group and the extended effects of macrolides, we conducted this detailed meta-analysis of the effects of macrolides in children with RAD, such as bronchiolitis, recurrent wheezing, and asthma.

Methods
=======

This systematic review and meta-analysis were conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines ([Table S1](#SD3-dddt-12-3825){ref-type="supplementary-material"}).[@b44-dddt-12-3825] We searched the following databases from inception to the end of August 2018: Embase, PubMed, and the Cochrane Library and the Cumulative Index to Nursing and Allied Health Literature (CINAHL). We used the keywords "Asthma" or "Chronic cough" or "infantile asthma" or "wheezing" or "wheez\*" and "Erythromycin" or "Azithromycin" or "Zithromax" or "Clarithromycin" or "macrolide(s)" in our search. Our strategy is shown in [Table S2](#SD4-dddt-12-3825){ref-type="supplementary-material"}. To ensure a comprehensive search, we did not limit the language, year or type of publication. Two authors (W-TL and S-JL) conducted the search independently, and disagreements were resolved through discussion with the third author (T-LY).

Study selection and methodological quality assessment
-----------------------------------------------------

After the initial search, two independent reviewers (W-TL and T-LY) scanned each abstract from the search publications to identify trials that met the inclusion criteria for systematic review and meta-analysis. Two review authors (W-TL and T-LY) independently reviewed the full-text articles of the retrieved trials that met the inclusion criteria. The randomized controlled trials (RCTs) included met all of the following eligibility criteria: 1) focused on human children aged \<18 years; 2) included a control group, including concurrent use of inhaled corticosteroid (ICS), Montelukast, long-acting and short-acting bronchodilators, in the study design; 3) included the use of a macrolide such as troleandomycin, erythromycin, azithromycin, or clarithromycin by the intervention group; 4) investigated the efficacy of macrolide treatment in children with asthma/recurrent wheezing/chronic bronchitis/acute bronchiolitis; and 5) provided data for clinical disease control and serological biomarkers change. We excluded the following: 1) articles irrelevant to the topic, 2) duplicate publications and populations, 3) trials of a crossover study design, and 4) studies without sufficient data for extracting or calculating the pooled analysis. Quality assessment of all included studies was conducted independently by four researchers (M-CT, H-HC, Y-JC, and HHL) using the Cochrane review risk of bias assessment tool.[@b45-dddt-12-3825] The adequacy of randomization, allocation concealment, blinding methods, implementation of the intention-to-treat analysis, dropout rate, complete outcome data, selective data reporting, and other biases was assessed. Each domain was categorized as low, high, or unclear.

Data extraction and analysis
----------------------------

Five authors (M-CT, H-HC, Y-JC, HHL, and CYL) independently extracted the data from all included studies, and the following data were collected: first author's name, year of publication, country of publication, number of patients, age of patients, sex ratio of patients, number of patients in the intervention and control groups, type of intervention (including the length of treatment), concomitant treatment and baseline medications, clinical outcome measures (including the timing of the outcome in relation to the treatment and the outcome persistent after treatment), and severe adverse effects.

Meta-analysis
-------------

Because of the significant heterogeneity expected among the participants of all the included studies, a random-effect model was used rather than the fixed-effect model.[@b46-dddt-12-3825] Comprehensive Meta-Analysis software version 3 (Biostat, Englewood, NJ, USA) was used for all the analyses. Dichotomous data were calculated using an OR or risk ratio with 95% CI. Difference in means (MD) or standardized difference in means (SMD) with 95% CI was used for analysis of continuous outcomes. Heterogeneity was quantified with the *Q* test and *I*^2^ statistics to evaluate the dispersion of the true effect of the included trials.[@b47-dddt-12-3825] Publication bias was evaluated by visual inspection of the funnel plots and Egger's tests.[@b48-dddt-12-3825] Subgroup analysis was performed to further analyze the effects of clinical variables as possible origins of heterogeneity, such as duration of macrolides, type of macrolides, and the different age group. Finally, meta-regression analyses were conducted only when data could be assessed throughout more than five trials.

Results
=======

Description of studies and quality assessment
---------------------------------------------

Initial database searching disclosed the following results: 568 studies in PubMed, 1,363 studies in Embase, 440 studies in Cochrane, and 60 studies in CINAHL. Of these 2,431 articles, we excluded 939 articles because of the duplications of studies. Of the remaining 1,492 articles, we excluded another 1,437 studies on the basis of title and abstract alone and retained 55 studies. Among the 55 studies, 16 studies were non-RCTs, 8 studies were without sufficient data for pooled analysis, 7 studies included participants over 18 years of age, 1 study used antibiotics other than macrolides as intervention medications, and the baseline controller medications between the intervention and control group in one study were different. Therefore, a total of 22 RCTs were included in our systemic review. [Figure 1](#f1-dddt-12-3825){ref-type="fig"} shows the searching process. Most of the included studies showed low bias using the Cochrane assessment tool.

Demographics
------------

Among the 22 RCTs, a total of 2,091 participants with ages ranging from 0 to 18 years were enrolled. These studies were held worldwide, with eight studies in the USA;[@b32-dddt-12-3825],[@b37-dddt-12-3825],[@b42-dddt-12-3825],[@b49-dddt-12-3825]--[@b51-dddt-12-3825] three trials in Brazil;[@b52-dddt-12-3825]--[@b54-dddt-12-3825] two trials each in Australia/New Zealand[@b55-dddt-12-3825],[@b56-dddt-12-3825] and Bangladesh;[@b57-dddt-12-3825],[@b58-dddt-12-3825] and one trial each in the Philippines,[@b59-dddt-12-3825] Taiwan,[@b40-dddt-12-3825] Turkey,[@b60-dddt-12-3825] Greece,[@b61-dddt-12-3825] Italy,[@b62-dddt-12-3825] Denmark,[@b43-dddt-12-3825] and Canada.[@b41-dddt-12-3825] Eight RCTs enrolled children with an underlying asthma diagnosis with or without hospitalization or an ED visit, mostly aged more than 5 years;[@b32-dddt-12-3825],[@b40-dddt-12-3825],[@b49-dddt-12-3825]--[@b51-dddt-12-3825],[@b59-dddt-12-3825],[@b61-dddt-12-3825],[@b62-dddt-12-3825] 11 studies enrolled toddlers hospitalized because of bronchiolitis aged less than 3 years 37,41,43,52--58,60,63,64 and 2 trials recruited children aged 12--71 months with recurrent wheezing with an ED visit.[@b41-dddt-12-3825],[@b42-dddt-12-3825] Three studies shared identical patient groups with different outcome assessments.[@b37-dddt-12-3825],[@b56-dddt-12-3825],[@b63-dddt-12-3825] Other characteristics of the included trials are listed in [Table 1](#t1-dddt-12-3825){ref-type="table"}.

Intervention
------------

Among the 22 eligible studies using macrolides as adjunctive therapy, azithromycin was the most commonly used macrolide in the included studies, comprising 13 trials.[@b37-dddt-12-3825],[@b41-dddt-12-3825]--[@b43-dddt-12-3825],[@b51-dddt-12-3825]--[@b56-dddt-12-3825],[@b62-dddt-12-3825]--[@b64-dddt-12-3825] Five studies used clarithromycin.[@b32-dddt-12-3825],[@b40-dddt-12-3825],[@b59-dddt-12-3825]--[@b61-dddt-12-3825] Two studies used troleandomycin.[@b49-dddt-12-3825],[@b50-dddt-12-3825] Two studies used erythromycin.[@b57-dddt-12-3825],[@b58-dddt-12-3825] The dose and duration of supplemented macrolides were in the following ranges: 5--12 mg/kg/day for 3--14 days and 30 mg/kg/week for 8 weeks, 5--15 mg/kg/day for 5 days to 4 weeks and 250 mg/day or 250 mg on alternate days for 2 weeks or 12 weeks with azithromycin, clarithromycin, and troleandomycin, respectively. Systemic steroids were prescribed concomitantly in school-aged children with underlying asthma in two trials[@b49-dddt-12-3825],[@b50-dddt-12-3825] and in preschool children with hospitalizations/ED visits in two trials,[@b41-dddt-12-3825],[@b52-dddt-12-3825] respectively. ICSs were used in most studies (6/7) in school-aged children with an asthma diagnosis and all trials (3/3) in preschool children with recurrent wheezing. For studies that enrolled toddlers (all \<2 years of age) hospitalized for acute bronchiolitis, an ICS was not used in any of the studies (0/9), and concomitant non-macrolide antibiotics were used in the minority (3/9).

Outcome measurement
-------------------

### Meta-analysis investigating the long-term effects of macrolides and placebo among children with asthma, recurrent wheezing and bronchiolitis

#### Is macrolide treatment beneficial to the pulmonary function of children with asthma and recurrent wheezing?

A total of four studies[@b49-dddt-12-3825],[@b50-dddt-12-3825],[@b59-dddt-12-3825],[@b62-dddt-12-3825] including 59 children and 3 studies[@b50-dddt-12-3825],[@b59-dddt-12-3825],[@b62-dddt-12-3825] including 49 children were enrolled for meta-analysis to determine the FEV~1~% and forced expiratory flow (FEF) 25%--75% after treatment. All the participants in the corresponding trials were children with asthma, and children in almost all (three of four) studies were aged more than 6 years. Two[@b49-dddt-12-3825],[@b50-dddt-12-3825] of the four studies enrolled children with severe, steroid-dependent asthma. The post-treatment FEV~1~% of children with asthma was significantly higher in the macrolide group than those in the placebo group (MD=−9.77, 95% CI=−14.18 to −5.35, *P*\<0.001; *I*^2^=0%, *τ*=0.000) ([Figure 2A](#f2-dddt-12-3825){ref-type="fig"}). Although there was publication bias (*t* value=12.31, *df*=2, *P*=0.007), the results of the meta-analysis did not change (MD=−10.33, 95% CI=−14.60 to −6.06) after the trim and fill test (with two potentially missing studies to the left of the mean). The significance of the results became nonsignificant after deleting the study by Chiong et al[@b59-dddt-12-3825] who enrolled children with FEV~1~% \<80% before treatment and used clarithromycin 15 mg/kg/day for 3 weeks (MD=−5.03, 95% CI=−15.67--5.61, *P*=0.354). In general, macrolides were seldom used for more than 2 weeks for the purpose of antimicrobial effects. In addition, we found that participants in the included studies (listed in [Table 1](#t1-dddt-12-3825){ref-type="table"}) could be approximately grouped into two categories according to the duration of treatment: less than 3 weeks (12 articles) and more than 3 weeks (8 articles). Therefore, we tried to do subgroup analysis according to the duration of macrolides, although the heterogeneity was not significant. The results of subgroup meta-analysis of trials showed a significantly better treatment effect on FEV~1~% in children who took macrolides for more than 3 weeks (MD=−10.09, 95% CI=−14.75 to −5.43, *P*\<0.001; *I*^2^=0%) ([Figure 2B](#f2-dddt-12-3825){ref-type="fig"}). Meanwhile, the post-treatment FEF 25%--75% of children with asthma in the macrolide group was also better than those in the placebo group (MD=−14.14, 95% CI=−26.11 to −2.18, *P*=0.02; *I*^2^=29.563%, *τ*=6.532) ([Figure 2C](#f2-dddt-12-3825){ref-type="fig"}). There was no significant publication bias (*t* value=0.086, *df*=1, *P*=0.945). The result became nonsignificant by removing the studies by Piacentini et al (MD=−14.01, 95% CI=−29.36 to 1.34, *P*=0.074)[@b62-dddt-12-3825] or Chiong et al (MD=−2.29, 95% CI=−21.12 to 16.55, *P*=0.812).[@b59-dddt-12-3825]

Does macrolide therapy decrease the need for rescue SABA usage?
---------------------------------------------------------------

In the four RCTs[@b37-dddt-12-3825],[@b41-dddt-12-3825],[@b43-dddt-12-3825],[@b60-dddt-12-3825] including 430 participants, macrolides were associated with significantly fewer SABA usage days throughout the follow-up periods (SMD=−0.34, 95% CI=−0.59 to −0.09, *P*=0.007) ([Figure 3A](#f3-dddt-12-3825){ref-type="fig"}). There was neither significant heterogeneity (*Q* value=4.112, *df*=3, *P*=0.250, *I*^2^=27.047%, *τ*=0.133) nor publication bias (*t* value=1.526, *df*=2, *P*=0.266). However, after removing data from the study by Stokholm et al,[@b43-dddt-12-3825] which used azithromycin 10 mg/kg/day for 3 days in children aged 1--3 years, the results showed no significant difference between the macrolides and placebo group (SMD=−0.30, 95% CI=−0.66 to 0.06, *P*=0.098). The included studies were composed of preschool children hospitalized for bronchiolitis or who presented to the ED with wheezing.

It was possible to perform subgroup analysis by dividing the four trials into two groups according to the type of macrolides. Azithromycin (n=356) was used in three RCTs. The results showed significantly less SABA usage days in children with bronchiolitis using macrolides (SMD=−0.32, 95% CI=−0.53 to −0.11, *P*=0.003, *I*^2^=0.000%) ([Figure 3B](#f3-dddt-12-3825){ref-type="fig"}). However, there were insufficient data for studies using non-azithromycin macrolides since only one study used clarithromycin.

Does macrolide treatment lower the risk of recurrent wheezing?
--------------------------------------------------------------

For the risk of recurrent wheezing, 115 participants in the macrolides group showed significantly less recurrent wheezing (SMD=−0.53, 95% CI=−0.81 to −0.26, *P*\<0.001, *I*^2^=0%, *τ*=0.000) ([Figure 4](#f4-dddt-12-3825){ref-type="fig"}) than the 99 patients in the placebo group among the selected three studies.[@b53-dddt-12-3825],[@b54-dddt-12-3825],[@b61-dddt-12-3825] There was no significant publication bias (*t* value=6.522, *df*=1, *P*=0.097). The enrolled children in the three studies were composed of school-aged children with intermittent mild to persistent asthma[@b61-dddt-12-3825] and toddlers less than 1-year-old hospitalized for acute bronchiolitis and the follow-up time were 3 months in two studies and 6 months in one study.[@b53-dddt-12-3825],[@b54-dddt-12-3825]

Does macrolide therapy alter the upper airway bacteria?
-------------------------------------------------------

In three studies[@b55-dddt-12-3825],[@b56-dddt-12-3825],[@b64-dddt-12-3825] including 325 children less than 2 years of age hospitalized for bronchiolitis, patients in the macrolides group showed significantly less *Moraxella catarrhalis* by nasal swab (OR=0.19, 95% CI=0.11--0.35, *P*\<0.001) ([Figure 5](#f5-dddt-12-3825){ref-type="fig"}). There was neither significant heterogeneity (*Q* value=0.731, *I*^2^=0%, *P*=0.694, *τ*=0.000) nor publication bias (*t* value=4.660, *df*=1, *P*=0.134). The significance was not changed after removing any single study.

### Adverse events

Compared with the placebo, participants in the macrolides group were associated with a lower risk to develop any adverse events (risk ratio=0.83, 95% CI=0.70--0.98, *P*=0.024, *I* [@b2-dddt-12-3825]=0%, *τ*=0.000, RCTs=7) ([Figure 6A](#f6-dddt-12-3825){ref-type="fig"}). There was no significant publication bias (*t* value=1.525, *df*=5, *P*=0.188). After removing the study by Mandhane et al,[@b41-dddt-12-3825] the results showed no significant difference between the macrolides and placebo groups (risk ratio=0.87, 95% CI=0.57--1.32, *P*=0.517). Most of the reported adverse events were related to gastrointestinal upset, such as nausea, vomiting, and abdominal pain. However, there were no enough data to do subgroup analysis according to the category of adverse events. It was possible to perform subgroup analysis according to the type of macrolides and the age of participants. The results showed that participants taking azithromycin (risk ratio=0.83, 95% CI=0.70--0.98, *P*=0.024, RCTs=5) but not troleandomycin (risk ratio=1.00, 95% CI=0.12--8.61, *P*=1.000) had lower risk of adverse effects ([Figure 6B](#f6-dddt-12-3825){ref-type="fig"}). Preschool children also had a lower risk of developing any adverse events (risk ratio=0.82, 95% CI=0.70--0.97, *P*=0.021, RCTs=4) but school-aged children did not (risk ratio=1.458, 95% CI=0.252--8.428, *P*=0.674) ([Figure 6C](#f6-dddt-12-3825){ref-type="fig"}).

### Meta-regression

To examine the heterogeneity of the present analysis, we performed a meta-regression analysis using the male sex ratio and the duration of macrolides as moderators in the single meta-regression. We found that the effect of macrolides on the adverse events was not significantly confounded by the male sex ratio (slope=−0.549, *P*=0.183) ([Figure S1](#SD1-dddt-12-3825){ref-type="supplementary-material"}) and the duration of macrolides (slope=0.021, *P*=0.326) ([Figure S2](#SD2-dddt-12-3825){ref-type="supplementary-material"}).

Discussion
==========

The current meta-analysis summarizes the effects of macrolides in children; six RCTs suggested that the supplementation with macrolides improves both the FEV~1~% and the FEF 25% with a mean difference of 10.43% and 19.41%, respectively. Moreover, pooled results from four trials showed that participants taking macrolides had fewer days of rescue SABA usage and three studies found that macrolides lowered the risks of recurrent wheezing. Furthermore, macrolides decreased the growth of *M. catarrhalis* in the upper airway. Finally, compared with participants who were taking placebos, those who were taking macrolide therapy had fewer adverse events.

To the best of our knowledge, this is the first meta-analysis to comprehensively investigate the efficacy of macrolides on childhood RAD including asthmatic and asthma-like diseases, such as recurrent wheezing and acute bronchiolitis. Our analysis included both school-aged children with more definitive asthma diagnoses and preschool children with concerning respiratory problems mimicking or preceding asthma. Compared with the two recent meta-analyses[@b38-dddt-12-3825],[@b65-dddt-12-3825] that enrolled studies on both adult and childhood asthma and focused on the effectiveness of macrolides on chronic asthma control and acute exacerbations, our study supplied more information on the analysis of treatment efficacy not only on the usefulness of pulmonary function tests, subsequent SABA usage, recurrent wheezing, but also the pathogenic bacteria status and the adverse drug reactions. The stricter inclusion criteria (only RCTs in the meta-analysis), the more recent search, and the concentrated age group (only children less than 18 years of age) ensured that the current meta-analysis is more up-to-date than the previous studies.

Our results are consistent with previous reports with regard to the effects of macrolides in the improvement of FEV~1~% in patients with asthma.[@b38-dddt-12-3825] Nevertheless, the analysis of FEV~1~% in Kew et al only enrolled one study recruiting adolescents in the pooled nine trials. In the current analysis, we pooled four trials and further found that macrolides improve pulmonary functions in both the large and small airways in school-aged children. However, the optimal dose and duration of macrolide treatment needed to offer a potential positive effect have not yet been established.[@b37-dddt-12-3825] Among the included studies in Kew et al, subgroup analysis according to the duration of macrolides was not done. In the current study, we found that those who use macrolides for more than 3 weeks had an increase in FEV~1~% from such treatment ([Figure 2B](#f2-dddt-12-3825){ref-type="fig"}). Although the evidence is limited considering the scanty numbers of included studies in current analysis, it is worth noted that the positive effects of macrolides in lung function in Kew et al may related to the prolonged duration (ranged from 4 to 52 weeks), which were far more than the general treatment. The effectiveness of prolonged macrolides treatment may be contributed to the antimicrobial effects rather than anti-inflammatory effects, which was shown in adult asthma studies.[@b34-dddt-12-3825],[@b35-dddt-12-3825] In addition, either incident *M. pneumoniae* or recurrent/chronic *C. pneumoniae* infection was thought to be related to newly-onset asthma and asthma exacerbation, even in non-atopic patients.[@b15-dddt-12-3825],[@b66-dddt-12-3825] Moreover, azithromycin taken daily for 1 year also benefit adult with COPD[@b67-dddt-12-3825] but had no benefits for adult with asthma who had only 3 days of treatment.[@b68-dddt-12-3825] Therefore, it seems that an extended treatment of macrolides could indeed lower the carrier status of *C. pneumoniae/M. pneumoniae* and help to improve the pulmonary functions. Even though macrolides are characterized by their broad spectrum of activity against common community-acquired respiratory pathogens and are widely used as first-line therapy, drug resistance has emerged with some common respiratory pathogens, such as *Streptococcus pneumoniae*.[@b69-dddt-12-3825] Moreover, previous studies[@b70-dddt-12-3825] determined that preschool wheezing is associated with pulmonary bacterial infection such as *Haemophilus influenzae, S. pneumoniae*, and *M. catarrhalis*, and patients received significant benefits from various classes of antibiotic therapy, including amoxicillin, amoxicillin/clavulanic acid, cefuroxime, and trimethoprim-- sulfamethoxazole. The duration of these antibiotics varied, ranging from 2 to 16 weeks. Therefore, macrolides alone may not be enough to eradicate other respiratory pathogenic bacteria, which may also interfere the respiratory disease outcome. For those who take azithromycin, further studies are needed to make precise recommendations regarding the optimal duration, most appropriate, and safe macrolides to improve pulmonary functions in children with asthma.

As with the former meta-analysis[@b65-dddt-12-3825] that pooled two studies from children and adults for each and concluded that macrolide users had longer symptom-free days, our study demonstrated less SABA usage in the macrolides group. The subgroup analyses showed that children hospitalized for bronchiolitis received more benefits from macrolide therapy, especially in those who took azithromycin. Both participants infected by RSV and non-RSV showed better responses than those taking placebos (data not shown). In contrast to the previous meta-analysis that failed to demonstrate the advantage of macrolides for an exacerbation, current analysis revealed a lower risk of recurrent wheezing among children. Animal models[@b71-dddt-12-3825] had shown that azithromycin attenuated viral-dependent neutrophilic airway inflammation and was associated with decreased concentrations of BAL inflammatory mediators, such as IL-8 and granulocyte-macrophage colony-stimulating factor. In preschool children with recurrent wheezing, the cell profile from BAL also revealed neutrophil-mediated, but not eosinophil-mediated inflammation in the airway, which is often the situation in asthmatic adults.[@b70-dddt-12-3825],[@b72-dddt-12-3825] Therefore, the anti-neutrophilic properties of macrolides may serve as the mechanistic rationale for the prevention of recurrent wheezing. Furthermore, IL-8 is the main and potent neutrophilic activator and is characteristically elevated, especially during viral bronchiolitis, such as RSV infection.[@b37-dddt-12-3825] It may explain the better response to macrolides among those patients with bronchiolitis on the lower recurrent wheezing risk in our analysis. Moreover, Kloepfer et al[@b73-dddt-12-3825] had shown that co-detection of viruses with upper airway polysaccharide bacteria in children was associated with an increased risk of asthma exacerbation. The decreased carriage status of *M. catarrhalis* after macrolide treatment in our analysis ([Figure 5](#f5-dddt-12-3825){ref-type="fig"}) further strengthened this theory. Finally, the concentration of azithromycin in alveolar macrophage and BAL is 100-fold more than that in serum, and, together with their intracellular aggregated feature, results in a long half-life.[@b74-dddt-12-3825] The long-lasting effects may also be the reason for the improvement of long-term efficacy such as pulmonary function, less rescue medication usage, and lower risks of recurrent wheezing.

Nevertheless, there were insufficient data to be pooled to find the relationship between macrolides and residential bacteria other than *M. catarrhalis* in the airway. Further well-designed, placebo-controlled studies are required to clarify the influences of residential and pathogenic airway pathogens on the effect of macrolide therapy.

It is safe to take macrolides as the adjunctive therapy to treat childhood reactive disease in current analysis, especially for those who take azithromycin ([Figure 6B](#f6-dddt-12-3825){ref-type="fig"}). The safety of azithromycin had also been approved in adults who were treated with a longer duration for other disease ranged from 3 to 12 months in previous studies.[@b75-dddt-12-3825],[@b76-dddt-12-3825]

Limitations
===========

There are several limitations of this study. First, we could not perform the subgroup analysis because of the lack of studies, such as those regarding steroid dose reduction, time to respiratory symptoms relief, nasal IL-8, and concomitant medications, thereby limiting the strength of our analysis. Second, because of limited numbers of included trials, it was not possible to perform more meaningful meta-regressions to examine the impact of variables that may affect the heterogeneity of some constructed results in the current study. Third, some of the included trials had a small sample size and could not provide details on the randomization processes. Fourth, the following time in each study varied and may thus limit the usability in some results. Fifth, some reported results in current analysis were driven by one study[@b41-dddt-12-3825],[@b59-dddt-12-3825],[@b62-dddt-12-3825] within the analysis and may need more validation studies to make a stronger conclusion. Finally, we could not discover the precise pathophysiology behind our findings because of the basic limitation of the meta-analysis.

Conclusion
==========

The present meta-analysis adds new evidence to the current knowledge about macrolides treating childhood RAD such as asthma, recurrent wheezing, and bronchiolitis. First, using macrolides as adjunctive therapy can improve pulmonary functions in both large and small airways in school-aged children. In addition, azithromycin treatment can decrease the need for rescue SABA usage among preschool children with recurrent wheezing or bronchiolitis. Furthermore, the recurrent wheezing risks and upper airway *M. catarrhalis* growth could be lowered by macrolide supplementation in children with a history of wheezing. Finally, macrolide therapy exhibits fewer risks of adverse events, especially for preschool children and those who use azithromycin. Additional large RCTs focusing on the optimal dose, biochemical features behind the wheezing phenotype, the role of the colonization airway pathogens, and head-to-head comparison of different macrolides' efficacy and mechanism are required to validate these findings.
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Meta-regression scatter plot showing there was no correlation between adverse events risk and male sex ratio.
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Meta-regression scatter plot showing there was no correlation between adverse events risk and the duration of macrolides.

###### 

PRISMA-P checklist

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Section/topic                        ≥    Checklist item                                                                                                                                                                                                                                                                                                Reported on page ≥
  ------------------------------------ ---- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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                                                                                                                                                                                                                                                                                                                                                          abstract

  **Introduction**                                                                                                                                                                                                                                                                                                                                        

  Rationale                            3    Describe the rationale for the review in the context of what is already known.                                                                                                                                                                                                                                2, 3
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  Data items                           11   List and define all variables for which data were sought (eg, PICOS, funding sources) and any assumptions and simplifications made.                                                                                                                                                                           5--9

  Risk of bias in individual studies   12   Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.                                                                                        3, [Table S3](#SD5-dddt-12-3825){ref-type="supplementary-material"}

  Summary measures                     13   State the principal summary measures (eg, risk ratio, difference in means).                                                                                                                                                                                                                                   3

  Synthesis of results                 14   Describe the methods of handling data and combining results of studies, if done, including measures of consistency (eg, I^2^) for each meta-analysis.                                                                                                                                                         3

  Risk of bias across studies          15   Specify any assessment of risk of bias that may affect the cumulative evidence (eg, publication bias, selective reporting within studies).                                                                                                                                                                    3, [Table S3](#SD5-dddt-12-3825){ref-type="supplementary-material"}

  Additional analyses                  16   Describe methods of additional analyses (eg, sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.                                                                                                                                                                3

  **Results**                                                                                                                                                                                                                                                                                                                                             

  Study selection                      17   Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.                                                                                                                                               3, 4, [Fig 1](#f1-dddt-12-3825){ref-type="fig"}
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  Synthesis of results                 21   Present results of each meta-analysis done, including confidence intervals and measures of consistency.                                                                                                                                                                                                       6--11, [Fig 2](#f2-dddt-12-3825){ref-type="fig"}[](#f3-dddt-12-3825){ref-type="fig"}[](#f4-dddt-12-3825){ref-type="fig"}[](#f5-dddt-12-3825){ref-type="fig"}--[6](#f6-dddt-12-3825){ref-type="fig"}

  Risk of bias across studies          22   Present results of any assessment of risk of bias across studies (see Item 15).                                                                                                                                                                                                                               6--11

  Additional analysis                  23   Give results of additional analyses, if done (eg, sensitivity or subgroup analyses, meta-regression \[see Item 16\]).                                                                                                                                                                                         6--11, [Fig 2](#f2-dddt-12-3825){ref-type="fig"}, [Fig 3](#f3-dddt-12-3825){ref-type="fig"}, [Fig 6](#f6-dddt-12-3825){ref-type="fig"}

  **Discussion**                                                                                                                                                                                                                                                                                                                                          

  Summary of evidence                  24   Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (eg, healthcare providers, users, and policy makers).                                                                                                                            11--12

  Limitations                          25   Discuss limitations at study and outcome level (eg, risk of bias), and at review-level (eg, incomplete retrieval of identified research, reporting bias).                                                                                                                                                     14

  Conclusions                          26   Provide a general interpretation of the results in the context of other evidence, and implications for future research.                                                                                                                                                                                       14

  **Funding**                                                                                                                                                                                                                                                                                                                                             
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**Note:** © 2009 Moher et al.[@b99-dddt-12-3825] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Abbreviation:** PRISMA-P, Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols.

###### 

Searching strategy

  PubMed
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ((((((((((Asthma OR asthma\*))) OR infantile asthma) OR chronic cough) OR ((Bronchitis, Chronic OR chronic bronchitis))) OR ((Respiratory Sounds OR wheezing OR wheez\*))) OR (Bronchiolitis OR Bronchiolitides OR acute bronchiolitis)) OR (Bronchiolitis, Viral OR Viral Bronchiolitides))) in All Fields
  AND
  ((((((Erythromycin OR T-Stat OR Erycette OR Erymax OR Ilotycin))) OR ((Clarithromycin OR TE-031 OR A-56268 OR Biaxin))) OR macrolide) OR ((Azithromycin OR Azythromycin OR Sumamed OR Toraseptol OR Vinzam OR CP-62993 OR CP 62993 OR CP62993 OR Zithromax OR Azitrocin OR Azadose OR Ultreon OR Zitromax OR Goxal OR Zentavion))) in All Fields
  Filters: Child: birth-18 years
  **Embase**
  ('asthma' OR 'asthma'/exp OR asthma OR asthma\*) OR ('chronic bronchitis'/exp) OR ('abnormal respiratory sound'/exp) OR (infantile NEAR/3 asthma) OR (chronic NEAR/3 cough) OR (chronic NEAR/3 bronchitis) OR ('wheezing'/exp OR wheezing OR wheez\*) OR ('bronchiolitis'/exp) OR ('viral bronchiolitis'/exp) OR ((viral AND bronchiolitides OR bronchiolitis OR bronchiolitides OR acute) AND bronchiolitis) OR ((viral NEAR/3 bronchiolitides) OR bronchiolitis OR bronchiolitides OR (acute NEAR/3 bronchiolitis))
  AND
  ('erythromycin'/exp OR erythromycin OR 't stat'/exp OR 't stat' OR 'erycette'/exp OR erycette OR 'erymax'/exp) OR (('azithromycin'/exp OR azithromycin OR 'azythromycin'/exp OR azythromycin OR 'sumamed'/exp OR sumamed OR toraseptol OR 'vinzam'/exp OR vinzam OR 'cp 62993′/exp OR 'cp 62993′ OR cp) AND 62993 OR 'cp62993′/exp OR cp62993 OR 'zithromax'/exp OR zithromax OR 'azitrocin'/exp OR azitrocin OR 'azadose'/exp OR azadose OR 'ultreon'/exp OR ultreon OR 'zitromax'/exp OR zitromax OR goxal OR zentavion) OR ('clarithromycin'/exp OR clarithromycin OR 'te 031′/exp OR 'te 031′ OR 'a 56268′/exp OR 'a 56268′ OR 'biaxin'/exp OR biaxin) OR ('macrolides'/exp OR macrolides OR 'macrolide'/exp OR macrolide)
  AND
  (\[adolescent\]/lim OR \[child\]/lim OR \[infant\]/lim OR \[newborn\]/lim OR \[preschool\]/lim OR \[school\]/lim)
  **Cochrane**
  (MeSH descriptor: \[Asthma\] explode all trees) OR (MeSH descriptor: \[Bronchitis, Chronic\] explode all trees) OR (MeSH descriptor: \[Respiratory Sounds\] explode all trees) OR (MeSH descriptor: \[Bronchiolitis\] explode all trees) OR (MeSH descriptor: \[Bronchiolitis, Viral\] explode all trees) OR (Asthma or asthma\* or infantile asthma or chronic cough or chronic bronchitis or Respiratory Sounds or wheezing or wheez\*:ti,ab,kw (Word variations have been searched)) OR (Bronchiolitis or Bronchiolitides or acute bronchiolitis or Viral Bronchiolitides:ti,ab,kw (Word variations have been searched))
  AND
  (MeSH descriptor: \[Erythromycin\] explode all trees) OR (MeSH descriptor: \[Azithromycin\] explode all trees) OR (MeSH descriptor: \[Clarithromycin\] explode all trees) OR (MeSH descriptor: \[Macrolides\] explode all trees) OR (Erythromycin or T-Stat or Erycette or Erymax or Ilotycin:ti,ab,kw (Word variations have been searched)) OR (Azithromycin or Azythromycin or Sumamed or Toraseptol or Vinzam or CP-62993 or CP 62993 or CP62993 or Zithromax or Azitrocin or Azadose or Ultreon or Zitromax or Goxal or Zentavion:ti,ab,kw (Word variations have been searched)) OR (Clarithromycin or TE-031 or A-56268 or Biaxin:ti,ab,kw (Word variations have been searched)) OR (macrolides or macrolide\*:ti,ab,kw (Word variations have been searched))
  **CINAHL**
  (MH "Asthma+") OR ("chronic cough") OR (infantile asthma) OR (MH "Bronchitis, Chronic") OR (MH "Respiratory Sounds") OR (MH "Bronchiolitis") OR (asthma\* OR infantile asthma OR chronic cough OR chronic bronchitis OR Respiratory Sounds OR wheezing OR wheez\* OR Bronchiolitis OR Bronchiolitides OR acute bronchiolitis OR viral bronchiolitis OR Viral Bronchiolitides)
  AND
  ((MH "Erythromycin") OR "Erythromycin") OR (T-Stat OR Erycette OR Erymax OR Ilotycin) OR ((MH "Clarithromycin") OR "Clarithromycin") OR (TE-031 OR A-56268 OR Biaxin) OR ((MH "Antibiotics, Macrolide") OR "macrolide") OR ((MH "Azithromycin") OR "Azithromycin") OR (Sumamed OR Toraseptol OR Vinzam OR CP-62993 OR CP 62993 OR CP62993 OR Zithromax OR Azitrocin OR Azadose OR Ultreon OR Zitromax OR Goxal OR Zentavion)
  Narrow by Subject Age: all child

**Abbreviation:** CINAHL, Cumulative Index to Nursing and Allied Health.

###### 

Risk of bias assessment of each included study[a](#tfn6-dddt-12-3825){ref-type="table-fn"}

  Study validity domains                                Sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment   Incomplete outcome data   Selective outcome reporting   Other sources of bias
  ----------------------------------------------------- --------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- ----------------------------- -----------------------
  **Probiotics**                                                                                                                                                                                                                         
  Ball et al,[@b77-dddt-12-3825] 1990                   Unclear               Unclear                  Low                                      Low                              Low                       Unclear                       Low
  Kamada et al,[@b78-dddt-12-3825] 1993                 Low                   Low                      Low                                      Low                              Low                       Unclear                       Unclear
  Fonseca-Aten et al,[@b79-dddt-12-3825] 2006           Unclear               Unclear                  Unclear                                  Unclear                          High                      Low                           Unclear
  Piacentini et al,[@b80-dddt-12-3825] 2007             Low                   Unclear                  Low                                      Low                              Unclear                   Low                           Unclear
  Tahan et al,[@b81-dddt-12-3825] 2007                  Low                   Unclear                  Low                                      Low                              Low                       Low                           Unclear
  Rasul et al,[@b82-dddt-12-3825] 2008                  Low                   Low                      Low                                      Low                              High                      Low                           Unclear
  Strunk et al,[@b83-dddt-12-3825] 2008                 Unclear               Unclear                  Unclear                                  Unclear                          Low                       Low                           Unclear
  Kabir et al,[@b84-dddt-12-3825] 2009                  Low                   Unclear                  Unclear                                  Unclear                          Low                       Low                           Unclear
  Koutsoubari et al,[@b85-dddt-12-3825] 2012            Low                   High                     High                                     High                             Low                       Low                           Unclear
  Pinto et al,[@b86-dddt-12-3825] 2012                  Low                   Unclear                  Unclear                                  Unclear                          Low                       Low                           Unclear
  Mccallum et al,[@b87-dddt-12-3825] 2013               Low                   Low                      Low                                      Low                              Low                       Low                           Unclear
  Chiong-Manaysay and Andaya,[@b88-dddt-12-3825] 2014   Unclear               Unclear                  Unclear                                  Unclear                          Unclear                   Unclear                       Unclear
  Bacharier et al,[@b89-dddt-12-3825] 2015              Low                   Low                      Low                                      Low                              Low                       Low                           Unclear
  Beigelman et al, [@b90-dddt-12-3825] 2015 (letter)    Low                   Low                      Low                                      Low                              Low                       Low                           Unclear
  Beigelman et al,[@b91-dddt-12-3825] 2015              Low                   Low                      Low                                      Low                              Low                       Low                           Low
  Mccallum et al,[@b92-dddt-12-3825] 2015               Low                   Low                      Low                                      Low                              Low                       Low                           Low
  Silveira D'Azevedo et al,[@b93-dddt-12-3825] 2016     Unclear               Unclear                  Unclear                                  Unclear                          Unclear                   Unclear                       Unclear
  Stokholm et al,[@b94-dddt-12-3825] 2016               Low                   Low                      Low                                      Unclear                          Low                       Low                           Low
  Wan et al,[@b95-dddt-12-3825] 2016                    Low                   Low                      Unclear                                  Unclear                          Low                       Low                           Unclear
  Zhou et al,[@b96-dddt-12-3825] 2016                   Unclear               Unclear                  Low                                      Low                              Low                       Low                           Low
  Mandhane et al,[@b97-dddt-12-3825] 2017               Low                   Low                      Low                                      Low                              Unclear                   Low                           Low
  Pinto et al,[@b98-dddt-12-3825] 2017                  Unclear               Unclear                  Unclear                                  Unclear                          Unclear                   Unclear                       Unclear

**Notes:**

Each domain has been evaluated as being "High", "Low", or "Unclear" regarding the risk of bias following the guidelines of Cochrane. Collaboration's tool for assessing risk of bias, the thorough and original evaluation form is attached in the following pages. "Low" in all Domains would place a study at "Low Risk of Bias"; "High" in any of the Domains would place a study at "High Risk of Bias"; "Unclear" in any of the domains would place the study at "Unclear Risk of Bias".
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![The Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flow diagram.](dddt-12-3825Fig1){#f1-dddt-12-3825}

![(**A**) Forest plot of the decreased forced expiratory volume percentage (FEV~1~%) between the macrolides group and the placebo group. (**B**) Forest plot of subgroup analysis of FEV~1~% by the duration of macrolides. (**C**) Forest plot of the decreased forced expiratory flow (FEF) 25%--75% between the macrolides group and the placebo group.](dddt-12-3825Fig2){#f2-dddt-12-3825}

![(**A**) Forest plot of the SABA usage days between the macrolides group and the placebo group. (**B**) Forest plot of subgroup analysis of SABA usage days by the type of macrolides.\
**Abbreviations:** SABA, short-acting β2-agonist; std diff, standardized difference.](dddt-12-3825Fig3){#f3-dddt-12-3825}

![Forest plot of the recurrent wheezing risks between the macrolides group and the placebo group.\
**Abbreviation:** Std diff, standardized difference.](dddt-12-3825Fig4){#f4-dddt-12-3825}

![Forest plot of the nasal swab *Moraxella catarrhalis* between the macrolides group and the placebo group.](dddt-12-3825Fig5){#f5-dddt-12-3825}

![(**A**) Forest plot of the adverse events risks between the macrolides group and the placebo group. (**B**) Subgroup analysis of the adverse events risks by the type of macrolides. (**C**) Subgroup analysis of the adverse events risks by the age group.](dddt-12-3825Fig6){#f6-dddt-12-3825}

###### 

Characteristics of randomized controlled trials using macrolides on children with asthma, recurrent wheezing and bronchiolitis

  Reference                                    Country                 Population (M%:F%)                                                                         Age (range/mean±SD)                                   Intervention:control                                                                       Intervention                                                                   Concomitant/baseline medication (I:C) %                                                                               Outcome measure                                                                                                                                                                                                                                                                                                                                                                                                                       Severe adverse events (%)
  -------------------------------------------- ----------------------- ------------------------------------------------------------------------------------------ ----------------------------------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Ball et al 1990[@b49-dddt-12-3825]           USA                     15 children severe, steroid-requiring asthma                                               8--18 years (13.1±3.0) 13.8±3.0 vs 12.4±3.2           5:5:5                                                                                      Troleandomycin 250 mg QD × 2 days the QOD × 7 times, totally 2 weeks           Methyl-prednisolone 40 mg/1.73 m^2^                                                                                   Steroid dose reduction, symptoms scores, morning plasma cortisol concentration, FEV~1~, FVC, TGV, methacholine PC~20~, eosinophil count after 2 weeks, methylprednisolone clearance                                                                                                                                                                                                                                                   Nil
  Kamada et al 1993[@b50-dddt-12-3825]         USA                     18 children severe, steroid- requiring asthma (36%:64%)                                    6--17 years 14.3±2.9 vs 11.3±2.7                      6:7:5                                                                                      Troleandomycin 250 mg QD or QOD depending on steroid protocol for 12 weeks     Prednisolone ≥20 mg QOD, bronchodilator ≥4 times/day, theophylline, ICS 500--1,000 µg BID                             Steroid dose reduction, symptoms scores, need for extra prednisolone, PEFR, pre-bronchodilator FEV~1~, FEF 25%--75%, methacholine PC~20~, morning plasma cortisol concentration, urinary cortisol excretion, bone density, hip flexor strength after 12 weeks                                                                                                                                                                         Abnormal liver function (7.6%)
  Fonseca-Aten et al 2006[@b32-dddt-12-3825]   USA                     43 children history of recurrent wheezing/asthma with an AE to ED (74%:26%)                4--17 years 112.5 (62--187) vs 100 (50--181) months   22:21                                                                                      Clarithromycin 15 mg/kg/day, BID for 5 days, orally                            SABA (39 of 43), LABA (3 of 43), and/or ICS (12 of 43)                                                                serum/nasopharyngeal aspirates: TNF-α, IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, GM-CSF, RANTES, eotaxin, MIP-1α, MIP-1β, MCP-1; *Mycoplasma pneumoniae*, *Chlamydia pneumoniae* detection in nasopharyngeal swabs/serologic test; dyspnea, wheeze, cough, asthma score                                                                                                                                                      NR
  Piacentini et al 2007[@b62-dddt-12-3825]     Italy                   16 children hospitalized for asthma (75%:25%)                                              13.9±2.4 vs 12.9±2.6                                  8:8                                                                                        Azithromycin 10 mg/kg QD for 3 consecutive days/week × 8 weeks                 ICS (fluticasone, 100--200 µg/day; beclomethasone dipropionate, 200--400 µg/day), SABA as needed                      FEV~1~, FVC, FEF 25%--75%, bronchial hyper-responsiveness (expressed as the dose-- response slope of FEV~1~ fall after hypertonic saline inhalation, and induced sputum)                                                                                                                                                                                                                                                              NR
  Tahan et al 2007[@b60-dddt-12-3825]          Turkey                  21 infants hospitalized for RSV bronchiolitis, first episode of wheezing (57%:43%)         ≥7 months 2 (1--6) vs 2 (1--7)                        12:9                                                                                       Clarithromycin (15 mg/kg) QD × 3 weeks                                         β2-agonist (when SpO \<94%, [@b2-dddt-12-3825] RR \>60 breaths/min, wheezing on auscultation, respiratory distress)   Primary outcome: LOS; duration of need for O~2~, IVF and β2-agonist Secondary outcomes: changes in the IL-4, IL-8, eotaxin, IFN-γ levels, readmission rate 6 months after discharge                                                                                                                                                                                                                                                   NR
  Rasul et al 2008[@b57-dddt-12-3825]          Bangladesh              60 children hospitalized for bronchiolitis (72%:28%)                                       0--2 years (80% below 6 months)                       15:22:23                                                                                   Erythromycin orally                                                            O~2~(for those with SpO~2~, 95%) and nebulization                                                                     Progress of the symptoms after 72 hours, progress of the signs after 72 hours, outcomes of bronchiolitis (improved, deteriorated, hospital stay)                                                                                                                                                                                                                                                                                      NR
  Strunk et al 2008[@b51-dddt-12-3825]         USA                     55 children moderate-to-severe persistent asthma (58%:42%)                                 6--18 years (11.2±2.6)                                17:19:19                                                                                   Azithromycin 250 mg QD (for those 25--40 kg) or 500 mg QD (for those .40 kg)   Budesonide 400--800 µg BID; Serevent Diskus^®^ 50 µg BID (run-in/post randomized)                                     Primary outcome: time to inadequate asthma control *M. pneumoniae*, *C. pneumoniae* detection in nasal washes: PCR assays                                                                                                                                                                                                                                                                                                             NR
  Kabir et al 2009[@b58-dddt-12-3825]          Bangladesh              295 children hospitalized for breathing difficulty/chest indrawing (73%:27%)               ,24 months                                            99:99:97 IV ampicillin: oral erythromycin: no antibiotics (P-Ab: O-Ab: N-Ab)               P-Ab (50 mg/kg/dose 6 hourly IV) O-Ab (10 mg/kg/dose 6 hourly)                 Nebulized salbutamol at 0.15 mg/kg/6--8 hours, O~2~ inhalation (SpO~2~ \<90%), IVF maintenance                        18 symptoms/signs which were graded on a two-point recovery scale of "rapid" and "gradual", indicating improvement within "four days" and "beyond four days", respectively                                                                                                                                                                                                                                                            NR
  Koutsoubari et al 2012[@b61-dddt-12-3825]    Greece                  40 children intermittent/mild persistent asthma with an acute AE (45%:55%)                 6--14 years 9.1±2.7 vs 8.4±2.5                        18:22                                                                                      Clarithromycin 15 mg/kg × 3 weeks                                              Prophylactic treatment according to asthma control level (GINA) ICS (61.1:59.1)                                       Primary outcome: days without symptoms within subsequent 12 weeks. Secondary outcome: symptom-free days after first AE, number/severity of periods with loss of control, time to first loss of control, PEFR variability, duration of the index episode, FEV~1~, mean daily morning PEFR; RT-PCR in nasal wash samples                                                                                                                NR
  Pinto et al 2012[@b52-dddt-12-3825]          Brazil                  184 infants hospitalized with AB (60%:40%)                                                 ≥2 months 3.1±2.2 vs 3.1±2.3                          88:96                                                                                      Azithromycin 10 mg/kg/day × 7 days                                             Antibiotics (4.5:6.3); Steroid (4.5:7.3); bronchodilator (20.5:21.8)                                                  Primary outcomes: LOS, duration of O~2~ Other variables: antibiotic use, broncho-dilators use, admission to the PICU, immunofluorescence for adenovirus, parainfluenza, influenza, RSV                                                                                                                                                                                                                                                NR
  Mccallum et al 2013[@b55-dddt-12-3825]       Australia/New Zealand   96 children hospitalized, O~2~-required bronchiolitis (68%:32%)                            ≥18 months 5.3 (3--9.4) vs 5 (3--8.5)                 50:46                                                                                      Azithromycin (30 mg/kg), single large dose of oral liquid                      Antibiotics (72.0:70.0); Supplemental IVF (38.0:41.0)                                                                 Primary endpoints: LOS, duration of O~2~ Other outcomes: any respiratory-related readmissions in 6 months of discharge, identification of respiratory viruses and bacterial pathogens (RT-PCR/culture)                                                                                                                                                                                                                                Nil
  Chiong-Manaysay and Andaya 2014^59,a^        Philippines             23 children with FEV~1~ \<80% before treatment                                             Children                                              13:10                                                                                      Clarithromycin 15 mg/kg/day bid × 3 weeks                                      NR                                                                                                                    Asthma Control Test questionnaires and spirometry (FVC, FEV~1~, FEV~1~/FVC, FEF 25%--75% and PEFR) prior medication and after the study period                                                                                                                                                                                                                                                                                        NR
  Bacharier et al 2015 42                      USA                     443 children histories of recurrent, severe wheezing (62%:38%)                             12--71 months (41.5±16.5) 42.5±16.4 vs 40.2±16.6      223:220 RTIs 473:464                                                                       Azithromycin 12 mg/kg/day × 5 days                                             Albuterol 4 times daily for the first 48 hours/whenever needed at any time during the RTI                             Primary outcome: number of RTIs not progressing to a severe LRTI (prescription of oral corticosteroids) Secondary outcome: numbers of urgent care/ED visits, hospitalizations. Symptom scores, albuterol use, time to second RTI                                                                                                                                                                                                      Nil
  Beigelman et al 2015 [@b37-dddt-12-3825]     USA                     39 infants hospitalized with RSV bronchiolitis (59%:41%)                                   1--18 months (3.8±2.9) 3.7±3.7 vs 3.9±2.0             19:20                                                                                      Azithromycin 10 mg/kg/day × 7 days then 5 mg/kg/day × 7 days                   Antibiotic treatment (0:2); hypertonic saline treatment (1:0)                                                         Primary outcomes: serum and nasal lavage IL-8 levels, proportion of participants with ≥2 additional wheezing episodes after treatment Secondary outcomes: proportion of participants with ≥3 wheezing episodes, with diagnosed asthma, being-prescribed with ICS, the time to second and third episode, the number of, ED visits for respiratory symptoms, courses of OCS, days of rescue albuterol, days with respiratory symptoms   Nil
  Beigelman et al 2015 63                      USA                     39 children hospitalized with RSV infection (59%:41%)                                      1--18 months (3.8±2.9) 3.7±3.7 vs 3.9±2.0             19:20                                                                                      Azithromycin 10 mg/kg/day × 7 days then 5 mg/kg/day × 7 days                   Antibiotic treatment (0:2); hypertonic saline treatment (1:0)                                                         RSV load in nasal lavage samples obtained on randomization, day 8, and day 15                                                                                                                                                                                                                                                                                                                                                         Nil
  Mccallum et al 2015 56                       Australia/New Zealand   219 children hospitalized with bronchiolitis (62%:38%)                                     ≥24 months 5.7 (3--10) vs 5.6 (3--9)                  106:113 (LOS/6-month readmission) 59:74 (O~2~ duration) 100:110 (day 21 clinical review)   Azithromycin 30 mg/kg/dose weekly × 3 times                                    Nonmacrolide antibiotics prescribed prior to hospital (45.0:42.0); during hospital (61.0:60.0); IVF (23.0:20.0)       Primary endpoint: LOS, duration of O~2~, day 21 clinical review, 6 months readmission; microbiology: Nasopharyngeal swabs for virus/bacteria (RT-PCR/culture)                                                                                                                                                                                                                                                                         Nil
  Silveira D'Azevedo V et al 2016^53,a^        Brazil                  91 infants hospitalized with AB                                                            \<12 months                                           51:40                                                                                      Azithromycin × 7 days                                                          NR                                                                                                                    Wheezing and hospitalization in a follow-up 1, 3, and 6 months after the AB                                                                                                                                                                                                                                                                                                                                                           NR
  Stokholm et al 2016 [@b43-dddt-12-3825]      Denmark                 72 children recurrent asthma- like symptoms, troublesome lung symptoms ≥3 days (65%:35%)   1--3 years 2.0±0.6                                    74:74 episodes                                                                             Azithromycin 10 mg/kg/day × 3 days                                             ICS (84%:80%); Montelukast (64.0:57.0)                                                                                Primary outcome: duration of episodes of troublesome lung symptoms after initiation of treatment Secondary outcomes: time from treatment to the next episode of troublesome lung symptoms, episodes that turned into severe AE (need for oral steroids/hospitalization), and the duration of β2 agonist use after treatment                                                                                                           1:1 Hospitalized for AGE: 4 days after randomized Hospitalized for pneumonia: 20 days after randomized
  Wan et al 2016 [@b40-dddt-12-3825]           Taiwan                  56 children with mild persistent asthma (63%:37%)                                          5--16 years 10.1±3.1 vs 10.2±3.1                      36:20                                                                                      Clarithromycin 5 mg/kg/day × 4 weeks                                           Fluticasone propionate 50 µg/puff bid                                                                                 Childhood asthma control test, FEV~1~, FEF 25%--75%, FeNO, total IgE, absolute eosinophil count, ECP level                                                                                                                                                                                                                                                                                                                            NR
  Zhou et al 2016 64                           USA                     39 infants hospitalized with first RSV bronchiolitis (59%:41%)                             1--18 months (3.8±2.9) 3.7±3.7 vs 3.9±2.0             19:20                                                                                      Azithromycin 10 mg/kg/day × 7 days then 5 mg/kg/day × 7 days                   Antibiotic treatment (0:2); hypertonic saline treatment (1:0)                                                         Recurrent wheezing: assessed monthly over a year following the initial episode Microbiome sequencing ≥ changes in nasal lavage microbial communities following the study treatments                                                                                                                                                                                                                                                   Nil
  Mandhane et al 2017 [@b41-dddt-12-3825]      Canada                  222 children presenting to ED with wheezing (72%:28%)                                      12--60 months 34.8±13.6 vs 30.5±13.9                  110:112 (primary analysis); 87:82 (secondary analysis)                                     Azithromycin 10 mg/kg/day at day 1 then 5 mg/kg/day × 4 days (day 2--5)        Prior ED: ICS (62.7:58.9) SABA (35.5:36.6); At ED discharge: SABA (79.1:73.2) OCS (59.1:62.5) ICS (57.3:50.9)         Primary outcome: time (days) to respiratory symptoms resolution Secondary outcomes: the number of days children used a SABA during the 21 day follow-up, time to disease exacerbation during the following 6 months                                                                                                                                                                                                                   Nil
  Pinto et al 2017 54,a                        Brazil                  83 infants hospitalized with AB                                                            \<12 months                                           46:37                                                                                      Azithromycin × 7 days                                                          NR                                                                                                                    LOS, identification of respiratory viruses, recurrent wheezing/hospital readmission post-AB                                                                                                                                                                                                                                                                                                                                           NR

**Note:**

Studies have been only reported as abstracts.

**Abbreviations:** AB, acute bronchiolitis; AE, acute exacerbation; AGE, acute gastroenteritis; BHR, bronchial hyper-responsiveness; BID, twice per day; C, control; DRS, dose response slope; ECP, eosinophil cation protein; ED, emergency department; F, female; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity; FeNO, fractional exhaled nitric oxide; FEF 25%--75%, forced expiratory flow between 25% and 75% of vital capacity; GINA, Global Initiative For Asthma; GM-CSF, granulocyte-macrophage colony stimulating factor; I, intervention; ICS, inhaled corticosteroid; IL, interleukin; ICU, intensive care unit; IFN, interferon; IV, intravenous; IVF, intravenous fluid; LABA, long-acting inhaled β-agonist; LOS, length of stay; LRTI, lower respiratory tract infection; LTRA, leukotriene receptor antagonist; M, male; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; methacholine PC20, concentration of methacholine required to induce a 20% decrease in FEV~1~; NR, not reported; PEFR, peak expiratory flow rate; QD, every day; QOD, every other day; RR, respiratory rate; RSV, respiratory syncytial virus; RTI, respiratory tract infection; RT-PCR, real-time polymerase chain reaction; SpO~2~, saturation of peripheral oxygen; SABA, short-acting β-agonist; TGV, thoracic gas volume.
